Stephen Huhn
Directeur Technique/Scientifique/R&D chez CONTINEUM THERAPEUTICS, INC.
Fortune : - $ au 31/05/2024
Postes actifs de Stephen Huhn
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CONTINEUM THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2020 | - |
Historique de carrière de Stephen Huhn
Anciens postes connus de Stephen Huhn
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Directeur Technique/Scientifique/R&D | 17/06/2014 | 01/01/2016 |
| Corporate Officer/Principal | 01/01/2007 | 17/06/2014 | |
| Stanford University | Corporate Officer/Principal | - | - |
Formation de Stephen Huhn
| University of Arizona | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CONTINEUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
- Bourse
- Insiders
- Stephen Huhn
- Expérience
